| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| G408315-1ml |
1ml |
现货  |
|
| 别名 | 戈伐替尼 (E7050) |
|---|---|
| 英文别名 | 1,1-Cyclopropanedicarboxamide, N-[2-fluoro-4-[[2-[[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]amino]-4-pyridinyl]oxy]phenyl]-N'-(4-fluorophenyl)- |
| 规格或纯度 | Moligand™, 10mM in DMSO |
| 英文名称 | Golvatinib (E7050) |
| 生化机理 | Golvatinib (E7050) 是一种 c-Met 和 VEGFR-2 双抑制剂，IC50 为 14 nM 和 16 nM，不抑制 bFGF 刺激的 HUVEC 生长（高达 1000 nM）。1/2阶段。 |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 血管内皮生长因子受体 2 抑制剂 |
| 产品介绍 |
Golvatinib (E7050)是c-Met和VEGFR-2双重抑制剂，IC50分别为14 nM和16 nM，不抑制bFGF刺激的HUVEC生长(浓度高达1000 nM)。Golvatinib也能抑制多种肿瘤细胞的生长,包括MKN45\EBC-1\Hs746T和SNU-5.除此之外,golvatinib有效抑制HGF或VEGF诱导的生长,IC50值为17 nM和84 nM. 在MKN45\Hs746T\SUN-5和EBC-1肿瘤细胞系异种移植小鼠模型上,golvatinib显著抑制肿瘤的生长.在VEGF过表达的人胰腺癌细胞系KP-1 /VEGF异种移植小鼠模型中,E7050单一给药,可减少VEGFR-2的磷酸化,随后通过抑制VEGF/VEGFR-2介导的肿瘤血管生成从而抑制肿瘤的生长。 Information Golvatinib (E7050) is a dualc-MetandVEGFR-2inhibitor with IC50 of 14 nM and 16 nM, does not inhibit bFGF-stimulated HUVEC growth (up to 1000 nM). Phase 1/2. In vitro studies indicate that E7050 potently inhibits phosphorylation of both c-Met and VEGFR-2. E7050 also potently represses the growth of both c-met amplified tumor cells and endothelial cells stimulated with either HGF or VEGF. E7050 circumvents resistance to all of the reversible, irreversible, and mutant-selective EGFR-TKIs induced by exogenous and/or endogenous HGF in EGFR mutant lung cancer cell lines, by blocking the Met/Gab1/PI3K/Akt pathway in vitro. E7050 also prevents the emergence of gefitinib-resistant HCC827 cells induced by continuous exposure to HGF. In vivo In vivo studies using E7050 shows inhibition of the phosphorylation of c-Met and VEGFR-2 in tumors, and strong inhibition of tumor growth and tumor angiogenesis in xenograft models. Treatment of some tumor lines containing c-met amplifications with high doses of E7050 (50–200 mg/kg) induces tumor regression and disappearance. In a peritoneal dissemination model, E7050 shows an antitumor effect against peritoneal tumors as well as a significant prolongation of lifespan in treated mice. In another xenograft model research, tumors produced by HGF-transfected Ma-1 (Ma-1/HGF) cells are more angiogenic than vector control tumors and shows resistance to ZD1839. E7050 alone inhibits angiogenesis and retards growth of Ma-1/HGF tumors. E7050 combined with ZD1839 induces marked regression of tumor growth. cell lines：HMC-1 and COLO-205 Concentrations：5-5000 nM Incubation Time：3 days Powder Purity:≥99% |
| ALogP | 4.1 |
|---|
| 分子类型 | 小分子 |
|---|---|
| Isomeric SMILES | CN1CCN(CC1)C2CCN(CC2)C(=O)NC3=NC=CC(=C3)OC4=CC(=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F |
| 分子量 | 633.69 |
| Reaxy-Rn | 13067631 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=13067631&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 65 mg/mL (199.14 mM); Ethanol: 22 mg/mL (67.4 mM); Water: Insoluble; |
|---|
首页
400-620-6333
